FOLD Stock Recent News
FOLD LATEST HEADLINES
Amicus Therapeutics has recently seen its shares slide under $10, despite strong revenue growth. The company's products, Galafold and Pombiliti + Opfolda, have significant sales potential and are seeing good sales traction. Analyst firms are also largely positive on the company's prospects.
Amicus (FOLD) reports first-quarter 2024 results, wherein earnings beat the Zacks Consensus Estimate but sales miss the same. The company updates its financial guidance for 2024.
The headline numbers for Amicus Therapeutics (FOLD) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Amicus Therapeutics (FOLD) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.18 per share a year ago.
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?
PRINCETON, N.J., March 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in March.
Amicus' (FOLD) fourth-quarter earnings beat estimates while revenues meet the same. Stock down.
Amicus Therapeutics should deliver strong topline growth with expanding margins and increasing cash flows in 2024.
Amicus Therapeutics (FOLD) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.19 per share a year ago.
PRINCETON, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 28, 2024, at 8:30 a.m. ET to discuss financial results for the full-year ended December 31, 2023.